98%
921
2 minutes
20
Objectives: To build a data set capturing the whole breast cancer screening journey from individual breast cancer screening records to outcomes and assess data quality.
Methods: Routine screening records (invitation, attendance, test results) from all 79 English NHS breast screening centres between January 1, 1988 and March 31, 2018 were linked to cancer registry (cancer characteristics and treatment) and national mortality data. Data quality was assessed using comparability, validity, timeliness, and completeness.
Results: Screening records were extracted from 76/79 English breast screening centres, 3/79 were not possible due to software issues. Data linkage was successful from 1997 after introduction of a universal identifier for women (NHS number). Prior to 1997 outcome data are incomplete due to linkage issues, reducing validity. Between January 1, 1997 and March 31, 2018, a total of 11 262 730 women were offered screening of whom 9 371 973 attended at least one appointment, with 139 million person-years of follow-up (a median of 12.4 person years for each woman included) with 73 810 breast cancer deaths and 1 111 139 any-cause deaths. Comparability to reference data sets and internal validity were demonstrated. Data completeness was high for core screening variables (>99%) and main cancer outcomes (>95%).
Conclusions: The ATHENA-M project has created a large high-quality and representative data set of individual women's screening trajectories and outcomes in England from 1997 to 2018, data before 1997 are lower quality.
Advances In Knowledge: This is the most complete data set of English breast screening records and outcomes constructed to date, which can be used to evaluate and optimize screening.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11027252 | PMC |
http://dx.doi.org/10.1093/bjr/tqad023 | DOI Listing |
J Hum Genet
September 2025
Division of Integrative Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Comprehensive genomic profiling (CGP) expands treatment options for solid tumor patients and identifies hereditary cancers. However, in Japan, confirmatory tests have been conducted in only 31.6% of patients with presumed germline pathogenic variants (GPVs) detected through tumor-only testing.
View Article and Find Full Text PDFNPJ Precis Oncol
September 2025
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Breast cancer is a highly heterogeneous disease with diverse outcomes, and intra-tumoral heterogeneity plays a significant role in both diagnosis and treatment. Despite its importance, the spatial distribution of intra-tumoral heterogeneity is not fully elucidated. Spatial transcriptomics has emerged as a promising tool to study the molecular mechanisms behind many diseases.
View Article and Find Full Text PDFCell Death Dis
September 2025
Department of Endocrinology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510080, China.
In recent years, there has been a rapid increase in the incidence of thyroid carcinoma (TC). Our study focuses on the regulatory effect of circular RNAs on metabolism of TC, aiming to provide new insights into the mechanisms of progression and a potential therapeutic target for TC. In this study, we identified high expression levels of circPSD3 in TC tissues through RNA sequencing.
View Article and Find Full Text PDFJMIR Res Protoc
September 2025
Moores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
Background: Cancer screening nonadherence persists among adults who are deaf, deafblind, and hard of hearing (DDBHH). These barriers span individual, clinician, and health care system levels, contributing to difficulties understanding cancer information, accessing screening services, and following treatment directives. Critical communication barriers include ineffective patient-physician communication, limited access to American Sign Language (ASL) cancer information, misconceptions about medical procedures, insurance navigation difficulties, and intersectional barriers for multiply marginalized individuals.
View Article and Find Full Text PDFEur J Radiol
August 2025
Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Purpose: To evaluate whether AI-assisted ipsilateral tissue matching in digital breast tomosynthesis (DBT) reduces localization errors beyond typical tumor boundaries, particularly for non-expert radiologists. The technology category is deep learning.
Materials And Methods: The study consisted of two parts.